Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer

European Journal of Nuclear Medicine

Volumn 23, Issue 3, 1996, Pages 312-319

  Grünwald, Frank ^a   Schomburg, Axel ^a   Bender, Hans ^a   Klemm, Edzard ^a   Menzel, Christian ^a   Bultmann, Thomas ^a   Palmedo, Holger ^a   Ruhlmann, Jürgen ^a   Kozak, Beate ^a   Biersack, Hans Jürgen ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Differentiated thyroid cancer; Fluorine 18 fluorodeoxyglucose; Iodine 131; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; THYROGLOBULIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MALE; METABOLISM; METASTASIS; POSITRON EMISSION TOMOGRAPHY; SARCOIDOSIS; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; TUMOR DIFFERENTIATION; WHOLE BODY SCINTISCANNING;

ADULT; AGED; DEOXYGLUCOSE; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 9044246672     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00837630     Document Type: Article

References (27)

1. 131I in differentiated thyroid cancer. Clin Endocrinol 1985; 23: 81-86.
2. 201thallium imaging and serum thyroglobulin in the management of differentiated carcinoma. Cancer 1993; 71: 3767-3773.
3. 99mTechnetium-sestamibi uptake by recurrent Hürthle cell carcinoma of the thyroid. J Nucl Med 1992; 33: 1393-1395
4. 201thallium scintigraphy in the follow-up of differentiated thyroid carcinoma. In: Hollinger MA, ed. Handbook of targeted delivery of imaging agents. Boca Raton, Fl.: CRC Press; 1995: 249-256.
5. 99mTc-MIBI in the follow-up of differentiated thyroid carcinoma. Nucl Med 1991; 30: 115-124.
6. Strauss LG, Conti PS. The application of PET in clinical oncology. J Nucl Med 1991; 32: 623-648.
7. Hawkins RA, Hoh C, Dahlbom M, et al. PET cancer evaluation with FDG [editorial]. J Nucl Med 1991; 32: 1555-1557.
8. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987; 28: 910-914.
9. Sisson JC, Ackermann RJ, Meyer MA. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 1993; 77:1090-1094.
10. Fridrich L, Messa C, Landoni C, et al. PET/[F-18]FDG and I-131 scintigraphy in patients with thyroid carcinoma (ThC). Eur J Nucl Med 1994; 2: 780.
11. 18F-FDG-PET scanning - a diagnostic tool for detection of recurrent and metastatic differentiated thyroid cancers [abstract]. 68th annual meeting of the American Thyroid Association, Chicago 1994, p 9.
12. 18F]-deoxyglucose-PET (FDG-PFT) in der Nachsorge von Patienten mit differenziertem und medullärem Schilddrüsencarcinom. Nucl Med 1995; 34: 152.
13. Easton E, Coates D, McKusick A, et al. Concurrent FDG F-18 thyorid PET imaging in I-131 therapy patients. J Nucl Med 1995; 36: 197.
14. 18FDG whole-body PET in differentiated thyroid carcinoma. Nucl Med 1995; 34: 127-134.
15. Spiessl B, Beahrs OH, Hermanek P, et al. TNM-Atlas. Illustrierter Leitfaden zur TNM/pTNM-Klassifikation maligner Tumoren/International Union Against Cancer/Union Internationale Contre le Cancer (UICC). Berlin Heidelberg New York: Springer; 1993: 58.
16. Biersack HJ, Helpap B, Koch U, et al. Should treatment of highly differentiated thyroid carcinoma be conservative? Nucl Med 1983; 22: 20-23.
17. Grünwald F, Ruhlmann J, Ammari B, et al. Experience with a high-dose concept of differentiated metastatic thyroid cancer therapy. Nucl Med 1988; 27: 266-271.
18. Biersack HJ, Hotze A. The clinician and the thyroid. Eur J Nucl Med 1991; 18: 761-778.
19. Hotze AL, Briele B, Grünwald F, et al. Determination of serum human thyroglobulin (hTg) with a new IRMA system in patients with differentiated thyroid carcinoma. Radiol Diagn 1991; 32: 383-386.
20. Black EG, Sheppard MC. Serum thyroglobulin measurement in thyroid cancer: evaluation of "false" positive results. Clin Endocrinol 1991; 35: 519-520.
21. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, Degroot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994; 79: 98-105.
22. Lubin E, Mechlis-Frish S, Zatz S, et al. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. J Nucl Med 1994; 35: 257-262.
23. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35: 1647-1649.
24. Oyen WJG, Mudde AH, van den Broek WJM, Corstens FHM. Metastatic follicular carcinoma of the thyroid: reappearance of radioiodine uptake. J Nucl Med 1995; 36: 613-615.
25. 18F-fluorodeoxyglucose imaging in preoperative diagnosis of thyroid malignancy. Eur J Nucl Med 1988; 13: 502-506.
26. Adler LP, Bloom AD, Positron emission tomography of thyroid masses. Thyroid 1993; 3: 195-200.
27. Scott GC, Meier DA, Dickinson CZ. Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m-pertechnetate and iodine-131-sodium iodide. J Nucl Med 1995; 36: 1843-1845.